Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation  Johann Pratschke, Duska Dragun, Ingeborg A. Hauser, Sabine Horn, Thomas F. Mueller, Peter Schemmer, Friedrich Thaiss  Transplantation Reviews  Volume 30, Issue 2, Pages 77-84 (April 2016) DOI: 10.1016/j.trre.2016.02.002 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Association between acute rejection at one year after kidney transplantation and age of the recipient and donor, based on UNOS data from 108,188 patients transplanted during 1995 to 2008. Adapted from reference [37]. Reproduced with permission. Transplantation Reviews 2016 30, 77-84DOI: (10.1016/j.trre.2016.02.002) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Incidence of antibody-mediated rejection (AMR) in living-donor transplant patients with positive complement-dependent cytotoxicity (CDC) cross-match, high (>300) or low (<300) flow cross-match or no T-cell or B-cell cross‐match at the time of transplant, following desensitization protocols tailored according to risk level [83]. Reproduced with permission. Transplantation Reviews 2016 30, 77-84DOI: (10.1016/j.trre.2016.02.002) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Freedom from antibody-mediated rejection by year 1 post-transplant in deceased-donor kidney transplants (1990–2010) according to number of HLA A or B mismatches with 0 HLA DR mismatch, and number of HLA DR mismatches with 0 HLA A or B mismatch [10]. MM, mismatch. Reproduced with permission. Transplantation Reviews 2016 30, 77-84DOI: (10.1016/j.trre.2016.02.002) Copyright © 2016 The Authors Terms and Conditions